Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barr’s women’s health strategy goes to Plan B

Executive Summary

Barr acquires Women's Capital Corporation's emergency oral contraceptive Plan B. The company will continue to pursue over-the-counter status for Plan B; the emergency contraceptive is expected to be considered by FDA's Nonprescription Drugs & Reproductive Health Drugs Advisory Committees in mid-December (1"The Pink Sheet" Sept. 29, 2003, In Brief). Barr will also acquire "certain other assets and liabilities" from WCC...

You may also be interested in...



Barr Plan B OTC Should Not Be Kept Behind Pharmacy Counter, Cmte. Says

Barr's Plan B emergency contraceptive should be available without a prescription and not restricted to "behind-the-counter" distribution at pharmacies, FDA's Reproductive Health and Nonprescription Drugs Advisory Committees said Dec. 16

Barr Has Plan B For Plan B: Pharmacy Access May Help More Than OTC Switch

Barr believes "behind-the-counter" access for the Plan B emergency contraceptive may be a more significant opportunity for the product than over-the-counter access

Emergency contraception OTC

Women's Capital Corporation's application to switch its Plan B emergency contraceptive from Rx to OTC status is expected to be considered by FDA's Nonprescription Drugs and Reproductive Health Drugs Advisory Committees in mid-December. Both committees are tentatively scheduled to meet Dec. 16. A switch application for Plan B was filed April 21...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel